Skip to main content
    C

    Cytokinetics Inc (CYTK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $53.17
    -2.96 (-5.27%)

    Market Cap: $7.82B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Cytokinetics Inc (CYTK) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Cytokinetics reported revenue of $88.04M for the fiscal year ended Dec 31, 2025, up 376.6% from the year before. That year, net income was -$784.96M with a net margin of -891.6%, operating cash flow was -$510.01M and free cash flow was -$534.82M. The quarter ended Sep 30, 2026 had revenue of $47.56M and net income of -$190.07M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $106.41M, a compound annual decline of 2.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$88.04M+376.6%100.0%-695.4%-891.6%
    Dec 2024$18.47M+145.3%100.0%-2902.7%-3191.1%
    Dec 2023$7.53M-92.0%100.0%-6589.7%-6988.6%
    Dec 2022$94.59M+34.3%100.0%-342.8%-411.2%
    Dec 2021$70.43M+26.2%100.0%-264.5%-305.7%
    Dec 2020$55.83M+107.8%100.0%-168.3%-228.0%
    Dec 2019$26.87M-14.7%100.0%-368.0%-452.9%
    Dec 2018$31.50M+135.6%100.0%-282.3%-337.4%
    Dec 2017$13.37M-87.4%100.0%-848.3%-955.9%
    Dec 2016$106.41MN/A100.0%17.6%15.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$88.04M$18.47M$7.53M$94.59M$70.43M$55.83M$26.87M$31.50M$13.37M$106.41M
    Gross profit$88.04M$18.47M$7.53M$94.59M$70.43M$55.83M$26.87M$31.50M$13.37M$106.41M
    Research and development$416.03M$339.41M$330.12M$240.81M$159.94M$96.95M$86.13M$89.14M$90.30M$59.90M
    Operating income-$612.26M-$536.25M-$496.20M-$324.20M-$186.31M-$93.94M-$98.87M-$88.92M-$113.40M$18.69M
    Net income-$784.96M-$589.53M-$526.24M-$388.95M-$215.31M-$127.29M-$121.69M-$106.29M-$127.79M$16.45M
    EBITDAN/AN/AN/AN/A-$179.14M-$93.31M-$95.63M-$85.01M-$108.87M$19.89M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$47.56M$28.62M$19.36M$17.75M$1.94M$66.77M$1.58M$17.18M$463.00K$0$835.00K$1.67M
    Gross profit$48.01M$23.03M$16.80M$17.75M$1.94M$64.35M$0$17.18M$463.00K$0$835.00K$1.67M
    Operating income-$167.09M-$179.17M-$183.62M-$178.37M-$166.75M-$111.51M-$155.63M-$139.04M-$140.80M-$130.17M-$126.23M-$127.42M
    Net income-$190.07M-$198.76M-$206.03M-$183.03M-$306.18M-$134.37M-$161.38M-$150.02M-$160.54M-$143.32M-$135.64M-$136.90M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $1.16B exceeded cash and equivalents by $1.03B. Shareholder equity was negative, at -$659.63M, as total liabilities of $2.08B exceeded total assets of $1.42B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.42B$1.40B$824.32M$1.01B$841.32M$533.80M$289.81M$211.18M$294.81M$170.14M
    Current assets$916.98M$1.11B$628.05M$795.19M$535.67M$474.22M$233.75M$207.67M$274.30M$158.63M
    Cash and equivalents$122.52M$94.86M$113.02M$65.58M$112.67M$82.98M$36.43M$42.26M$125.21M$66.87M
    Total liabilities$2.08B$1.54B$1.21B$1.12B$597.46M$420.42M$300.75M$185.24M$184.97M$75.78M
    Short-term debt$41.18M$11.52M$10.08M$958.00K$14.86M$2.79M$4.62M$2.61M$0$2.50M
    Long-term debt$1.12B$645.60M$607.37M$609.62M$142.84M$135.71M$129.26M$39.81M$31.78M$27.38M
    Shareholder equity-$659.63M-$135.37M-$386.32M-$107.90M$243.86M$113.38M-$10.94M$25.93M$109.84M$94.36M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.82B$1.92B$1.27B$1.42B$1.44B$1.23B$1.26B$1.40B$1.44B$1.52B$808.08M$824.32M
    Total liabilities$2.15B$2.10B$2.10B$2.08B$1.96B$1.59B$1.53B$1.54B$1.45B$1.42B$1.20B$1.21B
    Cash and equivalents$203.43M$255.27M$129.84M$122.52M$225.47M$74.94M$73.68M$94.86M$46.89M$190.14M$119.98M$113.40M
    Shareholder equity-$321.17M-$173.49M-$826.57M-$659.63M-$521.12M-$368.72M-$266.41M-$135.37M-$13.91M$108.55M-$396.16M-$386.32M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$510.01M-$395.89M-$414.33M-$299.52M-$142.52M$8.94M-$90.91M-$101.22M-$101.76M$36.98M
    Capital expenditures$24.81M$3.91M$1.42M$11.34M$48.87M$11.05M$2.62M$889.00K$2.88M$1.60M
    Free cash flow-$534.82M-$399.80M-$415.75M-$310.85M-$191.39M-$2.11M-$93.53M-$102.10M-$104.64M$35.39M
    Dividends paidN/AN/A$18.46MN/AN/AN/AN/A$0$0$0
    Investing cash flow$16.67M-$553.10M$239.25M-$262.13M-$147.78M-$196.51M-$74.71M$5.13M-$65.83M-$52.08M
    Financing cash flow$524.46M$930.61M$221.32M$516.17M$319.98M$234.12M$159.79M$13.13M$225.92M$16.89M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$124.02M-$159.84M-$145.46M-$142.65M-$107.50M-$128.24M-$131.62M-$65.57M-$101.50M-$99.31M-$129.51M-$74.04M
    Capital expenditures$700.00K$4.33M$5.93M$5.64M$9.35M$4.14M$5.66M$1.29M$701.00K$1.92M$0$77.00K
    Free cash flow-$124.72M-$164.17M-$151.39M-$148.29M-$116.86M-$132.38M-$137.28M-$66.86M-$102.20M-$101.23M-$129.51M-$74.11M
    Last 12 quarters

    Frequently Asked Questions About CYTK

    What is Cytokinetics' annual revenue?

    Cytokinetics reported revenue of $88.04M for the fiscal year ended Dec 31, 2025.

    How fast is Cytokinetics' revenue growing?

    Revenue was up 376.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -2.4%.

    Is Cytokinetics profitable?

    No. Cytokinetics reported net income of -$784.96M for the fiscal year ended Dec 31, 2025, with a net margin of -891.6%.

    How much free cash flow does CYTK generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$510.01M minus capital expenditures of $24.81M produced free cash flow of -$534.82M.

    How much debt does Cytokinetics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $1.12B, short-term debt of $41.18M and cash and equivalents of $122.52M.